Yaron Werber

New Capabilities

Covering Genmab after the LiGeR-HN1 readout

Genmab's experimental head and neck cancer drug, petosemtamab, cut the risk of death in half when added to Merck's Keytruda in a late-stage trial. Shares hit a record on October 28, the company's third late-stage win in quick succession. Analysts at William Blair called the data 'exceedingly positive.'

Updated Nov 1